Nuclear Medicine Market Exhibits Slow Growth
By MedImaging International staff writers Posted on 20 Jun 2016 |
The slow growth of the global nuclear medicine market is driven by lower revenues from technetium-99m-related products and unfavorable USD exchange rates against major currencies. These are the latest findings of Medraysintell (Louvain-la-Neuve, Belgium), a provider of strategic intelligence for radiation healthcare.
According to the Medraysintell 2016 Nuclear Medicine World Market Report & Directory, the global market for nuclear medicine radiopharmaceuticals reached USD 4.3 billion in 2015, growing by just over 2% a year between 2013 and 2015. The slow growth is compensated by the rise in radiotherapeutics, which have grown by about 60% a year from 2013 to 2015, mostly driven by one product, Xofigo (Radium-223), an isotope of radium with an 11.4-day half-life manufactured by Bayer (Leverkusen, Germany).
While the global nuclear medicine market is currently stale, Medraysintell expects it to climb to USD 25 billion by 2030, based on several factors that indicate an increasing demand for nuclear medicine procedures. These include a wider use of nuclear medicine around the world in applications that diverge from traditional ncology and cardiology, and the introduction of new radiopharmaceuticals. The molybdenum-99 shortage issue, which is expected to be solved within the next two years with domestic U.S. reactors coming online, will also influence additional growth.
MEDraysintell also estimates that the nuclear medicine market would have reached over USD 4.7 billion in 2015, if it were not for influence of the negative exchange rate. When discounting this effect, the market would have exhibited an annual growth of more than 7% for the period 2013-2015. The 990–page report and directory describes and analyzes over 360 radiopharmaceuticals and radionuclides and more than 160 companies and institutions active in nuclear medicine.
Related Links:
Medraysintell
Bayer
According to the Medraysintell 2016 Nuclear Medicine World Market Report & Directory, the global market for nuclear medicine radiopharmaceuticals reached USD 4.3 billion in 2015, growing by just over 2% a year between 2013 and 2015. The slow growth is compensated by the rise in radiotherapeutics, which have grown by about 60% a year from 2013 to 2015, mostly driven by one product, Xofigo (Radium-223), an isotope of radium with an 11.4-day half-life manufactured by Bayer (Leverkusen, Germany).
While the global nuclear medicine market is currently stale, Medraysintell expects it to climb to USD 25 billion by 2030, based on several factors that indicate an increasing demand for nuclear medicine procedures. These include a wider use of nuclear medicine around the world in applications that diverge from traditional ncology and cardiology, and the introduction of new radiopharmaceuticals. The molybdenum-99 shortage issue, which is expected to be solved within the next two years with domestic U.S. reactors coming online, will also influence additional growth.
MEDraysintell also estimates that the nuclear medicine market would have reached over USD 4.7 billion in 2015, if it were not for influence of the negative exchange rate. When discounting this effect, the market would have exhibited an annual growth of more than 7% for the period 2013-2015. The 990–page report and directory describes and analyzes over 360 radiopharmaceuticals and radionuclides and more than 160 companies and institutions active in nuclear medicine.
Related Links:
Medraysintell
Bayer
Latest Industry News News
- Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.
- Bayer and Google Partner on New AI Product for Radiologists
- Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement
- IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering
- International Societies Suggest Key Considerations for AI Radiology Tools
- Samsung's X-Ray Devices to Be Powered by Lunit AI Solutions for Advanced Chest Screening
- Canon Medical and Olympus Collaborate on Endoscopic Ultrasound Systems
- GE HealthCare Acquires AI Imaging Analysis Company MIM Software
- First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors
- RSNA Unveils 10 Most Cited Radiology Studies of 2023
- RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More
- AI Medical Imaging Products to Increase Five-Fold by 2035, Finds Study
- RSNA 2023 Technical Exhibits to Highlight Latest Medical Imaging Innovations
- AI-Powered Technologies to Aid Interpretation of X-Ray and MRI Images for Improved Disease Diagnosis
- Hologic and Bayer Partner to Improve Mammography Imaging
- Global Fixed and Mobile C-Arms Market Driven by Increasing Surgical Procedures